1 Good RA. Agammaglobulinemia-a provocative experiment of nature[J]. Bull University Minn Hosp Minn Med Fdn, 1954, 26: 1-19.
2 Malphettes M, Gerard L, Galicier L, et al. Good syndrome: an adult-onset immunodeficiency remarkable for its high incidence of invasive infections and autoimmune complications[J]. Clin Infect Dis, 2015, 61(2): e13-19.
3 Gereige JD, Maglione PJ, Guenechea-Sola M. Delayed diagnosis of Good syndrome[J]. J Allergy Clin Immunol Pract, 2020, 8(4): 1396-1397.
4 Kelesidis T, Yang O. Good's Syndrome remains a mystery after 55 years: A systematic review of the scientific evidence[J]. Clin Immunol, 2010, 135(3): 347-363.
5 Shi Y, Wang C. When the Good syndrome goes bad: a systematic literature review[J]. Front Immunol, 2021, 12: 679556.
6 Wang CH, Chan ED, Perng CL, et al. Intravenous immunoglobulin replacement therapy to prevent pulmonary infection in a patient with Good's syndrome[J]. J Microbiol, Immunol Infect, 2015, 48: 229-232.
7 崔晓敬, 曹彬, 李一鸣, 等. Good's综合征一例[J]. 中华内科杂志, 2016, 10(55): 800-802.
8 Del Pino Molina L, Wentink M, van Deuren M, et al. Precursor B-cell development in bone marrow of Good syndrome patients[J]. Clin Immunol, 2019, 200: 39-42.
9 Tarr PE, Sneller MC, Mechanic LJ, et al. Infections in patients with immunodeficiency with thymoma(Good syndrome). Report of 5 cases and review of the literature[J]. Medicine, 2001, 80: 123-133.
10 刘 姿, 张文平, 马利军. 表现为支气管扩张迅速进展的good's 综合征1例[J]. 临床肺科杂志, 2017, 22(7): 1345-1347.
11 Gernez Y, Baker MG, Maglione PJ. Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy[J]. Transfusion, 2018, 58: 3056-3064.
12 Zaman M, Huissoon A, Buckland M, et al. Clinical and laboratory features of seventy-eight UK patients with Good's syndrome(thymoma and hypogammaglobulinaemia)[J]. Clin Exp Immunol, 2019, 195(1): 132-138.
13 Verne GN, Amann ST, Cosgrove C, et al. Chronic diarrhea associated with thymoma and hypogammaglobulinemia(Good's syndrome)[J]. South Med, 1997, 90: 444-446.
14 Hughes WS, Cerda JJ, Holtzapple P, et al. Primary hypogammaglobulinemia and malabsorption[J]. Ann Intern Med, 1971, 74: 903-910.
15 Jansen A, van Deuren M, Miller J, et al. Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective[J]. Clin Immunol, 2016, 171: 12-17.
16 Bernard C, Frih H, Pasquet F, et al. Thymoma associated with autoimmune diseases: 85 cases and literature review[J]. Autoimmun Rev, 2016, 15(1): 82-92.
17 Thongngarm T, Boonyasiri A, Pradubpongsa P, et al. Features and outcomes of immunoglobulin therapy in patients with Good syndrome at Thailand's largest tertiary referral hospital[J]. Asian Pac J Allergy Immunol, 2019, 37: 109-115.
18 Dong JP, Gao W, Teng GG, et al. Characteristics of Good's syndrome in China: a systematic review[J]. Chin Med J, 2017, 130(13): 1604-1609.
19 Marx A, Chan JK, Coindre JM, et al. The 2015 world health organization classification of tumors of the thymus: continuity and changes[J]. J Thorac Oncol, 2015, 10(10): 1383-1395.
20 Multani A, Gomez CA, Montoya JG. Prevention of infectious diseases in patients with Good syndrome[J]. Curr Opin Infect Dis, 2018, 31(4): 267-277.
21 Kelleher P, Misbah SA. What is Good's syndrome immunological abnormalities in patients with thymoma[J]. J Clin Pathol, 2003, 56: 12-16.
22 Souadjian JV, Enriquez P, Silverstein MN, et al. The spectrum of diseases associated with thymoma. Coincidence or syndrome?[J]. Arch Intern Med, 1974, 134: 374-379.
23 Wang CH, Chan ED, Perng CL, et al. Intravenous immunoglobulin replacement therapy to prevent pulmonary infection in a patient with Good's syndrome[J]. J Microbiol Immunol Infect, 2015, 48(2): 229-232.
24 Li Y, Yao Z, Jiang M, et al. Clinical manifestations and long-term prognosis of Good syndrome: Results from a single-center cohort study from China[J]. Mod Rheumatol, 2021, 31(5): 1019-1024.
25 王艳侠, 田新平, 张 垣, 等. Good 综合征10例临床分析[J]. 中华医学杂志, 2011, 91(21): 1490-1492.